Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)


Defining Bronchioloalveolar Carcinoma (BAC): One End of a Spectrum
Howard (Jack) West, MD

The clinical syndrome of BAC is characterized by spread primarily through the lungs, a higher proportion of never-smokers or light former smokers, a greater proportion of women, and often progresses more slowly than most other lung cancers. This clinical and radiographic (scans) scenario isn't necessarily seen only with “pure BAC” under the microscrope from a biopsy, but rather can be a spectrum from pure BAC to part non-invasive BAC pattern and part invasive adenocarcinoma, and on the other end of the continuum is invasive adenocarcinoma, as shown in the illustration of how these appear under a microscope.

Pure BAC Adenocarcinoma w/BAC Features Invasive Adenocarcinoma
Pure BAC Adeno w/BAC Features Invasive Adeno

It doesn't have to be "pure BAC" to behave like a BAC clinical picture. The variability in how BAC behaves is still poorly understood. Overall, invasive adenocarcinoma (without BAC) has a worse prognosis than adeno/BAC mix, but there's tons we don't know yet. Importantly, many of the amazing responders with what is called BAC actually have adenocarcinoma with BAC characteristics under the microscope. And the response rate on BAC trials of drugs like Iressa (gefitinib) and Tarceva (erlotinib) actually suggest that patients with adenocarcinoma with BAC characteristics may do better than pure BAC. One of the other complications is that there are two different types of pure BAC, mucinous and nonmucinous. In the BAC trial with Iressa, which I led and published recently, patients with mucinous pure BAC did very poorly, while those with the non-mucinous type did considerably better. In any event, most current trials for "patients with BAC" allow patients with pure BAC or adeno with BAC to participate, and then the trial tries to collect tissue from the tumors to figure out patterns of which patients are getting a benefit and which are not. Right now, we really don't know nearly enough about the different subtypes of BAC and how they will do with various treatments. But we're getting better all the time.

Next Previous link

Previous PostNext Post

Related Content

Blood Cancer OncTalk
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:

Forum Discussions

Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...

Hello and welcome to Grace.  I'm sorry you're going through this worry.  It is normal to watch a small very slow-growing solid nodule with once-a-year CT scans.  Anything less than a...

Thanks you very much. So in summary the course of action taken suggested by lung specalist (re scan in 12 months) seems appropriate? And a PET at this stage is probably...

I can't say what is appropriate for you that's only something your professionals with all your information can do.  However, when someone has a solid nodule less than a cm that...

A doctor wouldn't nor shouldn't suspect a pancoast tumor with the info you've given.  It's like being in Colorado and hearing hoof beats and assuming it is zebras and not horses. ...

Hello and welcome to Grace.  I'm sorry you're worrying about this but it probably isn't cancer. 


From Adenocarcinoma of the lung: from BAC to the future, "GGNs with diameter...

Recent Comments

Canyil, I'm sorry your…
By JanineT GRACE … on
I can't say what is…
By JanineT GRACE … on
Thanks you very much. So in…
By razp on
A doctor wouldn't nor…
By JanineT GRACE … on